Status:
COMPLETED
Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir once daily injection compared to insuli...
Eligibility Criteria
Inclusion
- Type 1 diabetes for more than 1 year
- Subject treated by any kind of insulin regimen and whatever the number of injections
- HbA1c = 7.5% and = 10%
Exclusion
- Type 2 diabetes
- Treatment by oral anti-diabetic drugs
- Severe medical conditions
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
520 Patients enrolled
Trial Details
Trial ID
NCT00117780
Start Date
June 1 2005
End Date
October 1 2006
Last Update
June 2 2017
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Aalst, Belgium, 9300
2
Novo Nordisk Investigational Site
Lille, France, 59037
3
Novo Nordisk Investigational Site
Luxembourg, Luxembourg, 2763